These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

122 related articles for article (PubMed ID: 33359084)

  • 1. Gain-of-"endocytic' function in mutant p53 cancer cells.
    Lakoduk AM; Lee CF; Chen PH
    Int J Biochem Cell Biol; 2021 Feb; 131():105905. PubMed ID: 33359084
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Mutant p53 amplifies a dynamin-1/APPL1 endosome feedback loop that regulates recycling and migration.
    Lakoduk AM; Roudot P; Mettlen M; Grossman HM; Schmid SL; Chen PH
    J Cell Biol; 2019 Jun; 218(6):1928-1942. PubMed ID: 31043431
    [TBL] [Abstract][Full Text] [Related]  

  • 3. EGFR Trafficking in Physiology and Cancer.
    Caldieri G; Malabarba MG; Di Fiore PP; Sigismund S
    Prog Mol Subcell Biol; 2018; 57():235-272. PubMed ID: 30097778
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Mutant p53 regulates Dicer through p63-dependent and -independent mechanisms to promote an invasive phenotype.
    Muller PA; Trinidad AG; Caswell PT; Norman JC; Vousden KH
    J Biol Chem; 2014 Jan; 289(1):122-32. PubMed ID: 24220032
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Mutant p53 induces EZH2 expression and promotes epithelial-mesenchymal transition by disrupting p68-Drosha complex assembly and attenuating miR-26a processing.
    Jiang FZ; He YY; Wang HH; Zhang HL; Zhang J; Yan XF; Wang XJ; Che Q; Ke JQ; Chen Z; Tong H; Zhang YL; Wang FY; Li YR; Wan XP
    Oncotarget; 2015 Dec; 6(42):44660-74. PubMed ID: 26587974
    [TBL] [Abstract][Full Text] [Related]  

  • 6. p53 gain-of-function mutations increase Cdc7-dependent replication initiation.
    Datta A; Ghatak D; Das S; Banerjee T; Paul A; Butti R; Gorain M; Ghuwalewala S; Roychowdhury A; Alam SK; Das P; Chatterjee R; Dasgupta M; Panda CK; Kundu GC; Roychoudhury S
    EMBO Rep; 2017 Nov; 18(11):2030-2050. PubMed ID: 28887320
    [TBL] [Abstract][Full Text] [Related]  

  • 7. FCHSD2 controls oncogenic ERK1/2 signaling outcome by regulating endocytic trafficking.
    Xiao GY; Schmid SL
    PLoS Biol; 2020 Jul; 18(7):e3000778. PubMed ID: 32678845
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Crosstalk between CLCb/Dyn1-Mediated Adaptive Clathrin-Mediated Endocytosis and Epidermal Growth Factor Receptor Signaling Increases Metastasis.
    Chen PH; Bendris N; Hsiao YJ; Reis CR; Mettlen M; Chen HY; Yu SL; Schmid SL
    Dev Cell; 2017 Feb; 40(3):278-288.e5. PubMed ID: 28171750
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Regulation of EGFR trafficking and cell signaling by Sprouty2 and MIG6 in lung cancer cells.
    Walsh AM; Lazzara MJ
    J Cell Sci; 2013 Oct; 126(Pt 19):4339-48. PubMed ID: 23868981
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Mutant p53 promotes tumor cell malignancy by both positive and negative regulation of the transforming growth factor β (TGF-β) pathway.
    Ji L; Xu J; Liu J; Amjad A; Zhang K; Liu Q; Zhou L; Xiao J; Li X
    J Biol Chem; 2015 May; 290(18):11729-40. PubMed ID: 25767119
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Differential parsing of EGFR endocytic flux among parallel internalization pathways in lung cancer cells with EGFR-activating mutations.
    Walsh AM; Lazzara MJ
    Integr Biol (Camb); 2014 Mar; 6(3):312-23. PubMed ID: 24445374
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Gain-of-function p53 activates multiple signaling pathways to induce oncogenicity in lung cancer cells.
    Vaughan CA; Singh S; Grossman SR; Windle B; Deb SP; Deb S
    Mol Oncol; 2017 Jun; 11(6):696-711. PubMed ID: 28423230
    [TBL] [Abstract][Full Text] [Related]  

  • 13. ILT4 inhibition prevents TAM- and dysfunctional T cell-mediated immunosuppression and enhances the efficacy of anti-PD-L1 therapy in NSCLC with EGFR activation.
    Chen X; Gao A; Zhang F; Yang Z; Wang S; Fang Y; Li J; Wang J; Shi W; Wang L; Zheng Y; Sun Y
    Theranostics; 2021; 11(7):3392-3416. PubMed ID: 33537094
    [No Abstract]   [Full Text] [Related]  

  • 14. DICER1 regulated let-7 expression levels in p53-induced cancer repression requires cyclin D1.
    Sun X; Tang SC; Xu C; Wang C; Qin S; Du N; Liu J; Zhang Y; Li X; Luo G; Zhou J; Xu F; Ren H
    J Cell Mol Med; 2015 Jun; 19(6):1357-65. PubMed ID: 25702703
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Mutant p53 drives invasion by promoting integrin recycling.
    Muller PA; Caswell PT; Doyle B; Iwanicki MP; Tan EH; Karim S; Lukashchuk N; Gillespie DA; Ludwig RL; Gosselin P; Cromer A; Brugge JS; Sansom OJ; Norman JC; Vousden KH
    Cell; 2009 Dec; 139(7):1327-41. PubMed ID: 20064378
    [TBL] [Abstract][Full Text] [Related]  

  • 16. P53 mutations in triple negative breast cancer upregulate endosomal recycling of epidermal growth factor receptor (EGFR) increasing its oncogenic potency.
    Shapira I; Lee A; Vora R; Budman DR
    Crit Rev Oncol Hematol; 2013 Nov; 88(2):284-92. PubMed ID: 23755891
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Gain-of-function mutant p53 promotes the oncogenic potential of head and neck squamous cell carcinoma cells by targeting the transcription factors FOXO3a and FOXM1.
    Tanaka N; Zhao M; Tang L; Patel AA; Xi Q; Van HT; Takahashi H; Osman AA; Zhang J; Wang J; Myers JN; Zhou G
    Oncogene; 2018 Mar; 37(10):1279-1292. PubMed ID: 29269868
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Mutant p53 inhibits miRNA biogenesis by interfering with the microprocessor complex.
    Garibaldi F; Falcone E; Trisciuoglio D; Colombo T; Lisek K; Walerych D; Del Sal G; Paci P; Bossi G; Piaggio G; Gurtner A
    Oncogene; 2016 Jul; 35(29):3760-70. PubMed ID: 26996669
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Genome-Wide Small RNA Sequencing Identifies MicroRNAs Deregulated in Non-Small Cell Lung Carcinoma Harboring Gain-of-Function Mutant p53.
    Datta A; Das P; Dey S; Ghuwalewala S; Ghatak D; Alam SK; Chatterjee R; Roychoudhury S
    Genes (Basel); 2019 Oct; 10(11):. PubMed ID: 31661871
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The exon 19-deleted EGFR undergoes ubiquitylation-mediated endocytic degradation via dynamin activity-dependent and -independent mechanisms.
    Wang T; Zhang J; Wang S; Sun X; Wang D; Gao Y; Zhang Y; Xu L; Wu Y; Wu Y; Liu F; Liu X; Liu S; Zhang Y; Wang Y; Zou L; Liu H
    Cell Commun Signal; 2018 Jul; 16(1):40. PubMed ID: 29976202
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.